Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie has announced that the FDA has extended its review of SKYRIZI (risankizumab-rzaa) for treating moderate to severe Crohn's disease by three months. This extension is to assess additional data concerning the on-body injector for this new indication. Previously, SKYRIZI was approved for treating moderate to severe plaque psoriasis and active psoriatic arthritis. This ongoing FDA review does not affect existing approved indications.
On February 28, 2022, AbbVie announced the submission of a supplemental New Drug Application (sNDA) to the FDA for IMBRUVICA (ibrutinib) to treat pediatric patients aged one year and older with chronic graft versus host disease (cGVHD). A New Drug Application for an oral suspension formulation was also submitted, aiming to provide a more suitable dosage form for younger patients. The iMAGINE clinical trial, which included 59 participants, showed an overall response rate of 78%. If approved, it would be the first FDA-approved treatment option for pediatric cGVHD.
Allergan, a subsidiary of AbbVie (NYSE: ABBV), announced the presentation of new data on its eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting from March 3-6 in Nashville, TN. Key presentations will focus on DURYSTA® (bimatoprost intracameral implant) and XEN® Gel Stent, highlighting findings two years post-FDA approval of DURYSTA. Research includes studies on efficacy, safety, and real-world effectiveness of these treatments, aiming to enhance outcomes for glaucoma patients.
AbbVie announced promising top-line results from the U-EXCEL Phase 3 study, revealing that upadacitinib (45 mg daily) met its primary endpoints for clinical remission and endoscopic response in adults with moderate to severe Crohn's disease. At week 12, 49% of patients achieved clinical remission versus 29% on placebo (p0.0001), and 46% achieved endoscopic response compared to 13% on placebo (p<0.0001). The safety profile was consistent with previous studies, with no new risks identified. Full results are to be presented in medical conferences and published in peer-reviewed journals.
AbbVie has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the FDA for treating major depressive disorder (MDD) as an adjunct therapy with ongoing antidepressants. The submission is backed by Phase 3 studies indicating significant improvement in depression scores. Two studies, 3111-301-001 and RGH-MD-75, demonstrated substantial changes in the Montgomery-Åsberg Depression Rating Scale after treatment. Safety profiles remained consistent with previous data, supporting the potential for addressing treatment gaps for patients with MDD.
The board of directors of AbbVie declared a quarterly cash dividend of $1.41 per share, payable on May 16, 2022. Stockholders of record by April 15, 2022 will receive this dividend. Since its inception in 2013, AbbVie has increased its dividend by over 250%, making it a member of the S&P Dividend Aristocrats Index, which includes companies with at least 25 consecutive years of annual dividend increases.
Healis Therapeutics has secured ownership of a crucial botulinum toxin patent from AbbVie (NYSE: ABBV). This license transfer allows Healis to develop this treatment for Major Depressive Disorder (MDD), following successful results in eight Phase II trials. The acquisition is poised to expedite Healis' mission in the neuromuscular therapeutics space. However, it's important to note that, as of February 2022, botulinum toxin is still not FDA approved for MDD and remains under investigational use only.
Allergan Aesthetics, a subsidiary of AbbVie, announced the FDA's approval of JUVÉDERM® VOLBELLA® XC for improving infraorbital hollows in adults over 21. Clinical data indicates a high satisfaction rate, with 90% of patients content one year post-treatment. This new indication enhances Allergan's aesthetic portfolio, addressing significant patient needs. A training program for providers to ensure safe injection practices is mandatory. The product's characteristics aim to offer a smoother, effective solution for undereye treatments. JUVÉDERM® VOLBELLA® XC previously received FDA approval in 2016.
AbbVie announced robust financial results for Q4 2021, reporting worldwide net revenues of $14.886 billion, a 7.4% increase year-over-year. The immunology portfolio contributed $6.746 billion, while Humira's revenue reached $5.334 billion, showing a modest 3.5% rise. The company confirmed guidance of over $15 billion in combined sales for Skyrizi and Rinvoq by 2025. Notable FDA approvals for Rinvoq and Skyrizi expand treatment options, enhancing long-term growth prospects. Full-year 2022 EPS guidance is set between $9.26 and $9.46.
AbbVie (NYSE: ABBV) will showcase its IBD portfolio at the 17th Congress of ECCO from February 16-19, presenting 26 abstracts, including 8 oral and 10 poster presentations. These will focus on HUMIRA® and investigational treatments like risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®). Key analyses include the efficacy of risankizumab in Crohn's disease and the rapid symptom relief of ulcerative colitis with upadacitinib. AbbVie emphasizes its commitment to improve care for IBD patients through ongoing research and development.